Cytyc and Lakewood Pathology Associates Sign ThinPrep Imaging System Agreement.Business Editors/Health/Medical Writers BIOWIRE2K BOXBOROUGH, Mass. & LAKEWOOD, N.J.--(BUSINESS WIRE)--July 29, 2003 Cytyc Corporation (Nasdaq:CYTC) and Lakewood Pathology Associates today announced the completion of an agreement to install Cytyc's ThinPrep(R) Imaging System at Lakewood Pathology Associates' (LPA LPA Lysophosphatidic Acid LPA Apolipoprotein (A) LPA Local Planning Authority LPA Locally Preferred Alternative LPA Local Planning Agency LPA Link Pack Area LPA Left Pulmonary Artery LPA Law of Property Act ) New Jersey facility. The ThinPrep Imaging System is the first fully integrated, interactive computer system that assists cytotechnologists and pathologists in the primary screening and diagnosis of ThinPrep(R) Pap Test Pap test, Pap smear, or Papanicolaou test (păp'ənē`kəlou), medical procedure used to detect cancer of the uterine cervix. slides. The ThinPrep Imaging System combines revolutionary imaging technology with human interpretive expertise to improve cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. screening efficiency and performance. "We are excited to further strengthen our position on the leading edge of automated cervical cancer screening," said M. Nasar Qureshi, M.D., Ph.D., Lakewood Pathology Associates chairman and chief medical officer. "Lakewood Pathology is one of the first ThinPrep Pap Test facilities in the United States, so we are well aware of the unparalled clinical benefits of this cervical cancer screening technology. Implementation of the ThinPrep Imaging System will allow us to continue to grow our laboratory business while maintaining the clinical excellence that our customers have come to expect." "I am delighted that Lakewood Pathology will be one of our first ThinPrep Imaging System customers," said Patrick J. Sullivan, Cytyc Corporation's chairman, president, and chief executive officer. "Our relationship with LPA goes back to 1994, when it first implemented ThinPrep technology and then became an early adopter of the ThinPrep Pap Test shortly after FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval. Much has changed since those early days, but LPA's commitment to quality and excellence has remained constant." About Lakewood Pathology Associates, Inc. Lakewood Pathology Associates is a leading independent pathology practice located in the State of New Jersey providing a full range of anatomic pathology services, including surgical pathology surgical pathology n. A field in anatomical pathology concerned with examination of surgical specimens of tissues removed from living patients for the purpose of diagnosis of disease and guidance in the care of patients. , dermatopathology, oral pathology oral pathology n. The branch of dentistry concerned with the diseases of oral and paraoral structures, including oral soft tissues and mucous membranes and the teeth, jaws, and salivary glands. , cytopathology, hematopathology and molecular pathology. Accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. by the College of American Pathologists This article or section needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , Lakewood Pathology Associates has been recognized with distinction for exceptional service and quality. About Cytyc Corporation Cytyc Corporation designs, develops, manufactures, and markets the ThinPrep(R) System for use in medical diagnostic applications primarily focused on women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. . The ThinPrep System is widely used for cervical cancer screening and is the platform from which the Company has launched its expansion into breast cancer risk assessment with the FirstCyte(TM) Breast Test. The ThinPrep System consists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor, ThinPrep(R) Imaging System, and related reagents, filters, and other supplies. Cytyc is traded on The Nasdaq Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. under the symbol CYTC. Cytyc and ThinPrep are registered trademarks of Cytyc Corporation. FirstCyte is a trademark of Cytyc Corporation for which registration has been applied. For Cytyc Investors Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to the Company's financial condition, operating results and future economic performance, and management's expectations regarding future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and proprietary technology, uncertainty of product development efforts, product acceptance, management of growth, risks associated with competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and any healthcare reimbursement policies, risks associated with litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , and other risks detailed in the Company's filings with the Securities and Exchange Commission, including under the heading "Certain Factors Which May Affect Future Results" in its 2002 Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and its most recent Quarterly Report on Form 10-Q Form 10-Q See 10-Q. filed with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in Company expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion